Get the Stockscreener App
48.52
0.76%
-0.37
After Hours:
48.20
-0.32
-0.66%
Ptc Therapeutics Inc stock is traded at $48.52, with a volume of 790.85K.
It is down -0.76% in the last 24 hours and down -2.02% over the past month.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
See More
Previous Close:
$48.89
Open:
$48.91
24h Volume:
790.85K
Relative Volume:
0.69
Market Cap:
$3.85B
Revenue:
$900.66M
Net Income/Loss:
$-453.20M
P/E Ratio:
-8.1684
EPS:
-5.94
Net Cash Flow:
$-274.19M
1W Performance:
+5.64%
1M Performance:
-2.02%
6M Performance:
+10.57%
1Y Performance:
+35.49%
1-Day Range:
$48.02
$49.09
1-Week Range:
$46.11
$49.15
52-Week Range:
$28.72
$58.38
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Name
Ptc Therapeutics Inc
Sector
Industry
Phone
(908) 222-7000
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
48.52 | 3.64B | 900.66M | -453.20M | -274.19M | -5.94 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-07-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-11-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-07-25 | Initiated | Scotiabank | Sector Perform |
| Dec-13-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-03-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Aug-26-24 | Resumed | UBS | Buy |
| May-20-24 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-06-23 | Downgrade | Truist | Buy → Hold |
| Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
| Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
| Mar-17-23 | Initiated | SVB Securities | Market Perform |
| Dec-14-22 | Initiated | Goldman | Sell |
| Sep-12-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
| Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-11-19 | Initiated | Bernstein | Outperform |
| Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Ptc Therapeutics Inc Stock (PTCT) Latest News
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Ameriprise Financial Inc. - MarketBeat
Mackenzie Financial Corp Increases Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $74.00 at Wells Fargo & Company - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Quantinno Capital Management LP Invests $436,000 in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Toronto Dominion Bank Makes New $148.36 Million Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
BNP Paribas Financial Markets Has $465,000 Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
State of Wyoming Buys New Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Two Sigma Investments LP Sells 143,945 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages PTC Therapeutics, Inc. (PTCT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
RNA Targeting Small Molecule Drug Discovery Research Report 2025 - GlobeNewswire Inc.
Woodline Partners LP Acquires Shares of 155,883 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Millennium Management LLC Has $13.97 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Bank of America Corp DE - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Holdings Lifted by ProShare Advisors LLC - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Position Cut by Two Sigma Advisers LP - MarketBeat
Voloridge Investment Management LLC Sells 92,168 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (PTCT) Price Target Raised by Wells Fargo | PTCT Stock News - GuruFocus
PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
PTCT: Wells Fargo Increases Price Target for PTC Therapeutics | - GuruFocus
Evolving Landscape of Mitochondrial Disease Market: Key Insights of Latest Published Report—Leigh Syndrome, Leber’s Hereditary Optic Neuropathy, MELAS Syndrome, and Thymidine Kinase 2 Deficiency | DelveInsight - GlobeNewswire Inc.
PTC Therapeutics’ SWOT analysis: biotech stock faces pivotal year amid pipeline progress - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc.PTCT - Eastern Progress
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by Deutsche Bank AG - MarketBeat
Rafferty Asset Management LLC Reduces Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Nuveen Asset Management LLC Acquires 273,638 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Lazard Asset Management LLC Has $2.06 Million Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Muscular Dystrophy Treatment Market: Executive Briefing & - openPR.com
Huntington's Disease Pipeline 2025: Groundbreaking Clinical - openPR.com
Those who invested in PTC Therapeutics (NASDAQ:PTCT) three years ago are up 51% - Yahoo Finance
StockNews.com Downgrades PTC Therapeutics (NASDAQ:PTCT) to Buy - MarketBeat
Point72 Asset Management L.P. Purchases 867,502 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Point72 Hong Kong Ltd Grows Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Transcript : PTC Therapeutics, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 02 - marketscreener.com
14,998 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Bought by Graham Capital Management L.P. - MarketBeat
Parkman Healthcare Partners LLC Decreases Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
2025-05-19 | PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:PTCT | Press Release - Stockhouse
MPM Bioimpact LLC Buys 345,052 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages PTC Therapeutics, Inc. (PTCT) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results - Quantisnow
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Down – Here’s What Happened - Defense World
Ptc Therapeutics Inc Stock (PTCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):